Acticor Biotech SAS Past Earnings Performance
Past criteria checks 0/6
Acticor Biotech SAS's earnings have been declining at an average annual rate of -22.8%, while the Biotechs industry saw earnings growing at 7.7% annually.
Key information
-22.8%
Earnings growth rate
-4.4%
EPS growth rate
| Biotechs Industry Growth | 30.8% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Acticor Biotech SAS makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -16 | 5 | 10 |
| 31 Mar 24 | 0 | -18 | 6 | 11 |
| 31 Dec 23 | 0 | -19 | 6 | 12 |
| 30 Sep 23 | 0 | -19 | 5 | 12 |
| 30 Jun 23 | 0 | -19 | 5 | 11 |
| 31 Mar 23 | 0 | -17 | 5 | 11 |
| 31 Dec 22 | 0 | -16 | 5 | 10 |
| 30 Sep 22 | 0 | -15 | 5 | 9 |
| 30 Jun 22 | 0 | -14 | 5 | 8 |
| 31 Mar 22 | 0 | -13 | 5 | 8 |
| 31 Dec 21 | 0 | -13 | 4 | 8 |
| 30 Sep 21 | 0 | -11 | 3 | 8 |
| 30 Jun 21 | 0 | -10 | 2 | 8 |
| 31 Mar 21 | 0 | -9 | 2 | 7 |
| 31 Dec 20 | 0 | -8 | 2 | 6 |
| 31 Dec 19 | 0 | -5 | 2 | 4 |
| 31 Dec 18 | 0 | -6 | 2 | 4 |
Quality Earnings: ALACT is currently unprofitable.
Growing Profit Margin: ALACT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALACT is unprofitable, and losses have increased over the past 5 years at a rate of 22.8% per year.
Accelerating Growth: Unable to compare ALACT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALACT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-22.1%).
Return on Equity
High ROE: ALACT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.